MediciNova, Inc. (MNOV)
| Market Cap | 67.93M -11.2% |
| Revenue (ttm) | 409,657 |
| Net Income | -12.00M |
| EPS | -0.24 |
| Shares Out | 49.22M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 28,976 |
| Open | 1.400 |
| Previous Close | 1.410 |
| Day's Range | 1.380 - 1.405 |
| 52-Week Range | 1.168 - 1.960 |
| Beta | 0.63 |
| Analysts | Strong Buy |
| Price Target | 7.50 (+441.52%) |
| Earnings Date | May 14, 2026 |
About MNOV
MediciNova, Inc., a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. It develops MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent in Phase 2 clinical trial for treating neurological and other disorders, such as progressive multiple sclerosis, amyotrophic lateral sclerosis, chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, and glioblastoma, as well as prevention of acute res... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 4 analysts, the average rating for MNOV stock is "Strong Buy." The 12-month stock price target is $7.5, which is an increase of 441.52% from the latest price.
News
MediciNova’s peer-reviewed ibudilast study advances clinical translation
The company states: “MediciNova (MNOV) and the Standard Market of the Tokyo Stock Exchange announced that a study conducted by researchers at the Spanish National Cancer Research Centre has identified...
New Peer‑Reviewed Study Reveals Actionable Immune–Microenvironment Target in Brain Metastasis; Medicinova Advances Clinical Translation
LA JOLLA, Calif., April 27, 2026 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ: MNOV) and the Standard Market of the Tokyo Stock Exchange...
Maxim resumes MediciNova at Buy on potential value-driving data events this year
Maxim analyst Michael Okunewitch resumed coverage of MediciNova (MNOV) with a Buy rating and $6 price target The firm is positive on the company’s potential value-driving data events in 2026,…
MediciNova resumed with a Buy at Maxim
Maxim resumed coverage of MediciNova (MNOV) with a Buy rating and $6 price target
MediciNova to Participate at the 38th Annual ROTH Conference
LA JOLLA, Calif., March 16, 2026 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ: MNOV) and the Standard Market of the Tokyo Stock Exchange...
MediciNova initiated with a Buy at H.C. Wainwright
H.C. Wainwright initiated coverage of MediciNova (MNOV) with a Buy rating and $10 price target MediciNova is a clinical-stage biotechnology company developing multi-target small molecule therapies acr...
MediciNova management to meet with Maxim
Meeting to be held on February 26 hosted by Maxim.
MediciNova Announces 100 Patients Enrolled in SEANOBI Study Expanded-Access-Program (EAP) Evaluating MN‑166 (ibudilast) in ALS patients
LA JOLLA, Calif., Jan. 29, 2026 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock Exchange (...
MediciNova issues letter to shareholders
MediciNova (MNOV) provides shareholders a corporate update in the following Letter to Stockholders from CEO Yuichi Iwaki, M.D., Ph.D. “The year 2025 was marked by global uncertainty, with accelerating...
2026 New Year's Greetings from the CEO
LA JOLLA, Calif., Jan. 06, 2026 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (Nasdaq:MNOV) and the Standard Market of the Tokyo Stock Exchange (...
MediciNova initiated with a Buy at Lucid Capital
Lucid Capital analyst Elemer Piros initiated coverage of MediciNova (MNOV) with a Buy rating and $11 price target The firm says the company is in a pivotal trial with an…
MediciNova completes patient enrollment in neuropathy trial of MN-166
MediciNova (MNOV) completed patient enrollment in the Phase 2 clinical trial, the OXTOX study – Oxaliplatin Neurotoxicity study in patients with metastatic colorectal cancer -. This study is evaluatin...
MediciNova Announces Completion of Patient Enrollment Evaluating MN-166 (ibudilast) in the Prevention of Chemotherapy-induced Peripheral Neuropathy
LA JOLLA, Calif., Dec. 18, 2025 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock Exchange (...
MediciNova Announces Update and Basic Characteristic Randomized Patients' of Phase 2/3 Clinical Trial of MN-166 (Ibudilast) in ALS (COMBAT-ALS Clinical Trial) Presented at the 36th International Symposium on ALS/MND
LA JOLLA, Calif., Dec. 08, 2025 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company listed on the NASDAQ Global Market (NASDAQ: MNOV) and the Standard Market of the Tokyo Stock Exchange ...
MediciNova files $300M mixed securities shelf
16:26 EST MediciNova (MNOV) files $300M mixed securities shelf
MediciNova names Dr. Christopher Breder as Clinical and Regulatory Advisor
MediciNova (MNOV) is pleased to announce the appointment of Dr. Christopher D. Breder, MD, PhD as Clinical and Regulatory Advisor. Dr. Breder will provide strategic guidance for MediciNova’s Drug Deve...
MediciNova Appoints Dr. Christopher Breder, MD, PhD as Clinical and Regulatory Advisor
LA JOLLA, Calif., Nov. 18, 2025 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock Exchange (...
MediciNova Wins Contract Research and Development Innovation Award at 2025 BioTech Breakthrough Awards
LA JOLLA, Calif., Nov. 06, 2025 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock Exchange (...
MediciNova completes patient enrollment in MN-001-NATG-202 trial
MediciNova (MNOV) announces the completion of patient enrollment in its Phase 2 clinical trial, MN-001-NATG-202, evaluating MN-001 for the treatment of hypertriglyceridemia and non-alcoholic fatty liv...
MediciNova compounds demonstrate novel therapeutic approach for Atherosclerosis
MediciNova (MNOV) and the Standard Market of the Tokyo Stock Exchange announces the publication of a new research article in the peer-reviewed Journal of Atherosclerosis and Thrombosis, the official j...
MediciNova Compounds Demonstrate Novel Therapeutic Approach for Atherosclerosis in Peer-Reviewed Publication
Study published in the Journal of Atherosclerosis and Thrombosis demonstrates tipelukast (MN-001 and its metabolite MN-002) has influence on cholesterol metabolism in patients Study published in the J...
MediciNova to Present at the LD Micro Main Event XIX Investor Conference
LA JOLLA, Calif., Oct. 06, 2025 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ: MNOV) and the Standard Market of the Tokyo Stock Exchange ...
MediciNova completes patient enrollment in COMBAT-ALS Phase 2b/3 trial
MediciNova (MNOV) announced completion of patient enrollment in its Phase 2/3 clinical trial, COMBAT-ALS, evaluating MN-166 for the treatment of Amyotrophic Lateral Sclerosis. A total of 234 patients ...
MediciNova provides update on SEPA, COMBAT-ALS trial enrollment
The Company reported the signing of a Standby Equity Purchase Agreement for up to $30 million worth of common stock over the course of 36 months. Under that Agreement, the…
MediciNova Provides Shareholder Update on Key Developments
LA JOLLA, Calif., Sept. 08, 2025 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ: MNOV) and the Standard Market of the Tokyo Stock Exchange...